Wichita Urology Group

What Wichita Urology Group does

Wichita Urology Group (legal entity Wichita Urology, P.A.) is a physician-owned urology specialty practice headquartered in Wichita, Kansas, operating since 1963 with 13 board-certified/eligible physicians and 13+ advanced practice providers. The practice delivers comprehensive urologic care across general urology, urologic oncology, pediatric urology, and male/female pelvic health, with subspecialty expertise in robotic and minimally invasive surgery, including Holmium Laser Enucleation of the Prostate (HoLEP), Prostate Artery Embolization (PAE), sacral neuromodulation, and PSMA PET CT imaging using the Illuccix (Ga-68 gozetotide) tracer for prostate cancer staging.

Care is delivered through four Wichita campuses (East, West, Legacy Medical Arts, Clifton) and seven outreach clinics across Kansas in Anthony, Derby, El Dorado, Kingman, Newton, Pratt, Wellington, and Winfield. The practice operates an ACHC-accredited in-office dispensary at the East Campus for oral oncolytics and urologic medications, and runs a 24/7 Kidney Stone Hotline as a patient acquisition channel. An affiliated facility, Advanced Cancer Therapies, supports an active clinical trial portfolio with industry partners including Janssen, Merck, Bayer, Myovant, Propella, Urovant, Exact Sciences, Harbinger Health, Gregor Diagnostics, and Ortho Clinical Diagnostics.

The business model is insurance-based fee-for-service urology practice revenue augmented by dispensary margin, imaging service fees, and clinical trial site payments. Patient financing is supported through CareCredit. As of January 1, 2025, cash payments are no longer accepted, formalizing the practice as a fully insurance-dependent revenue model. The group is a member of the American Urologic Association and the Large Urology Group Practice Association (LUGPA), positioning it within the national independent urology group practice segment.

Name

Wichita Urology Group

Legal name

Wichita Urology, P.A.

Website

https://wichitaurology.com

Company type

Private

Founded year

1963

Operating status

Operating

Headcount range

51–100 employees

Short description

Wichita Urology Group is a physician-owned Kansas urology practice with 13 board-certified physicians and 13+ APPs delivering general, oncologic, and pediatric urology across four Wichita campuses and seven outreach clinics, plus an ACHC-accredited in-office dispensary and active clinical trial program.

Ownership category

akta.pro rank

Product category

Urology Healthcare Services

NAICS

Other Outpatient Care Centers (62149)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

General Urology (HLAKAOAA)

akta.pro secondary industries

Urolithiasis / Kidney Stone Centers (HLAKAOAG), Pediatric Urology (HLAKAOAE)

Keywords

• Urology care
• Prostate cancer treatment
• Kidney stone treatment
• Urologic oncology
• Minimally invasive surgery

Headquarters

HQ city

Wichita

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Patient Care Services: Medical services billed to insurance and patients for urology consultations, procedures, surgeries, and ongoing care across multiple conditions including BPH, kidney stones, incontinence, and urologic cancers.
2. In-Office Dispensary: Dispensing oral oncolytics and urologic medications directly to patients from the clinic location, providing a convenient revenue stream for cancer treatment support.
3. Clinical Trial Participation: Participation in clinical trials providing access to advanced procedures and treatments; medications and testing may be provided at no cost to patients while generating research revenue.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Wichita Urology Group is a private urology medical practice operating across four main campuses in Wichita, Kansas and seven outreach clinics throughout the state. The group of 13 board-certified/eligible physicians and 13+ advanced practice providers delivers diagnostic imaging including PSMA PET CT, medical management, robotic and minimally invasive surgery, pediatric urology, urologic oncology, and an ACHC-accredited in-office dispensary for oral oncolytics. Services span general urology, BPH, kidney stone treatment, erectile dysfunction, incontinence, and urologic cancers.

Product overview

Wichita Urology Group is a comprehensive urology practice consisting of 13 board-certified/eligible physicians offering general and specialized urology services. The practice operates across multiple locations in Wichita, KS with outreach clinics throughout Kansas. Core services include general urology, robotic and minimally invasive surgery, pediatric urology, and urologic oncology. The practice offers specialized diagnostic imaging including PSMA PET CT with Illuccix tracer, and treatment procedures such as Prostate Artery Embolization (PAE), HoLEP, Urowave therapy, penile implants, and sacral neuromodulation. Additional services include an ACHC-accredited in-office dispensary for oral oncolytics, a 24/7 Kidney Stone Hotline, and an active clinical trials program for urological cancers.

Differentiator

Problem solved

Functional benefit

Products and services

• General Urology Services Comprehensive urology care provided by 13 board-certified/eligible physicians for conditions including prostate disease, male infertility, erectile dysfunction, incontinence, stone disease, and urinary oncology, including robotic and minimally invasive surgical capabilities.
• Pediatric Urology Services Specialized urology care for pediatric patients provided by fellowship-trained pediatric urologists including Dr. Kahlil Saad and Dr. Kenneth Schmanke, supported by pediatric APP Kelsie Hoffman.
• PSMA PET CT Imaging State-of-the-art Positron Emission Tomography-Computed Tomography imaging that combines functional PET imaging with detailed anatomical CT information for precise detection, staging, and monitoring of prostate cancer and other conditions.
• Illuccix (Gallium Ga 68 Gozetotide) PSMA-Targeted Imaging Advanced PSMA-targeted imaging tracer used with PET scans to detect prostate-specific membrane antigen in prostate cancer cells, helping determine treatment eligibility and disease extent.
• Prostate Artery Embolization (PAE) Minimally invasive, image-guided procedure using catheter-based injection of tiny particles to block blood flow to the prostate, causing shrinkage and relieving BPH symptoms without surgery.
• In-Office Physician Dispensary On-site dispensary at 2626 N Webb Rd that dispenses oral oncolytics for cancer treatment and other urologic medications, providing patients convenient access to therapy at home. Accredited by the Accreditation Commission for Health Care (ACHC).
• Kidney Stone Hotline 24/7 hotline (1.833.627.8663) for individuals experiencing kidney stone symptoms, providing rapid assessment and directing patients to appropriate care pathways.
• Clinical Trials Program Participation in clinical research through Advanced Cancer Therapies and Wichita Urology Group, offering patients access to advanced treatment options including trials for bladder cancer, prostate cancer, and cancer detection.
• Urowave Therapy (Li-ESWT) Non-invasive erectile dysfunction treatment using low-intensity extracorporeal shock wave therapy to enhance blood flow and promote tissue regeneration. Typically requires six 15-minute sessions.
• Penile Implant Procedure Surgical treatment for erectile dysfunction involving placement of inflatable or malleable implants inside the penis to enable erection for sexual activity.
• Sacral Neuromodulation (Axonics, Medtronic Interstim) Nerve stimulation therapy using an implanted bladder pacemaker device for treatment of overactive bladder and urinary incontinence with high success rates.
• HoLEP (Holmium Laser Enucleation of the Prostate) Minimally invasive laser procedure for prostate enlargement offered exclusively by Dr. Patrick Houghton, the only urologist in the area to provide this treatment.
• Kidney Stone Treatments Comprehensive kidney stone management including conservative treatment, Shock Wave Lithotripsy (ESWL), Ureteroscopy with Laser Lithotripsy, and Percutaneous Nephrolithotomy (PCNL).
• Overactive Bladder (OAB) Treatment Program Center for Urinary Health team providing comprehensive overactive bladder treatment including behavioral therapies, medications, and advanced interventions with Taylor Trent, APRN as OAB Champion.

Quantifiable outcome

• Only urologist in the area offering Holmium Laser Enucleation of the Prostate (HoLEP)

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Janssen (Johnson & Johnson)coreStrategic or Co-development PartnerClinical trial collaboration for bladder cancer (TAR-200 plus cetrelimab, TAR-200 alone vs BCG) and prostate cancer studies (apalutamide). Provides patients access to advanced therapies not otherwise available.
• MerckcoreStrategic or Co-development PartnerClinical trial collaboration for pembrolizumab (Keytruda) in combination with BCG for high-risk non-muscle invasive bladder cancer.
• BayercoreStrategic or Co-development PartnerClinical trials for darolutamide (Nubeqa) in prostate cancer treatment, including real-world effectiveness studies and trials for metastatic hormone-sensitive prostate cancer.
• Myovant SciencescoreStrategic or Co-development PartnerClinical trial collaboration for ORGOVYX (relugolix) in prostate cancer treatment, generating real-world evidence on safety and effectiveness.
• UrovantminorStrategic or Co-development PartnerClinical trial for vibegron in pediatric neurogenic detrusor overactivity (NDO) in patients using clean intermittent catheterization.
• Propella TherapeuticsminorStrategic or Co-development PartnerPhase 1/2a clinical trial for PRL-02 depot in advanced prostate cancer treatment.
• Exact SciencesminorStrategic or Co-development PartnerCancer detection clinical trial using CancerSEEK plasma-based testing for early cancer detection.
• Harbinger HealthminorStrategic or Co-development PartnerMulti-center observational study collecting biospecimens and clinical data for early cancer detection test development.
• Gregor DiagnosticsminorStrategic or Co-development PartnerCancer detection clinical trial involving semen sample collection for prostate cancer diagnostic test development.
• Advanced Cancer TherapiescoreStrategic or Co-development PartnerAffiliated facility providing advanced cancer therapies. Physicians and staff devote time to clinical research for improved urological cancer treatments.
• Kansas GastroenterologyminorStrategic or Co-development PartnerCollaboration for early feasibility study of neuromodulation in patients with inflammatory bowel disease (IBD).
• Ortho Clinical DiagnosticsminorStrategic or Co-development PartnerClinical study to substantiate use of VITROS Total PSA III test as an aid in prostate cancer detection.

Scale indicators4 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• United Urology Group: Growth-oriented large urology group practice platform also affiliated with the Large Urology Group Practice Association alongside Wichita Urology Group. Directly comparable in business model (multi-physician urology specialty practice with ancillary services and clinical trials).
• Oregon Urology Institute: Independent specialty urology group with research institute and ambulatory surgery center — comparable operating model spanning clinical care, advanced procedures, and clinical trials.
• Genesis Healthcare Partners: Multi-specialty urology and gastroenterology platform with multiple locations across California; comparable subspecialty model with in-office ancillaries, clinical research, and outpatient-center operations.
• U.S. Urology Partners: PE-backed platform of large urology group practices across multiple U.S. states. Highly comparable in scale, subspecialty breadth, and clinical-trial infrastructure, and represents the consolidation strategy Wichita Urology Group may eventually face as a competitor or acquirer.
• Michigan Institute of Urology: Michigan-based independent large urology group with a comparable roster of subspecialists, multiple offices, robotic/oncology/stone programs, and clinical research. Highly comparable Midwest-style independent community urology practice.
• Idaho Urologic Institute: Independent multi-physician urology group with subspecialty coverage, research program, and advanced procedures. Comparable community-urology scale with diverse service lines, situated in a non-major-metro market similar to Wichita.
• Chesapeake Urology: Large Mid-Atlantic urology specialty group practice with multiple locations, subspecialists, in-office dispensing, and active clinical trials. Closely aligned with Wichita Urology Group in scale, breadth of subspecialty services, and oncology-ancillary revenue model.
• The Urology Group (Cincinnati): Independent multi-physician urology specialty group serving the Cincinnati tri-state region with multiple campuses, subspecialty coverage, oncology, robotic surgery, and clinical research—closely mirroring Wichita Urology Group's full-service community-urology model.
• Skyline Urology: Large multi-location urology group practice focused on advanced diagnostics (including PET imaging) and minimally invasive treatment—a close functional analogue to Wichita Urology's PSMA PET CT and robotic/laser surgery offering.

Regional players

• Kansas City Urology Care: Multi-physician urology practice serving the Kansas City metro area (overlapping Kansas/Missouri geography). Comparable in urology subspecialty services and community-urology scale, making it a relevant regional competitor for patient referrals along the Wichita–KC corridor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@wichitaurology7867/videos
• Xx.com/WichitaUrology
• Facebookfacebook.com/wichitaurology

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wichita Urology Group